While clinical implementation of these findings will require further in‐depth studies on this topic, the report by Smith et al (2017) is a significant step forward in our understanding of the biology of melanoma on BRAF inhibitor treatment and also suggests that novel combination therapies may be designed at preventing early resistance. The gene discussed is BRAF; the disease is melanoma.